Acrobiosystems Co

Acrobiosystems Co Inventory/Revenue

The Inventory to Revenue Ratio of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 31.47 %. In the previous year, Inventory to Revenue Ratio was 30.56 % — a change of 2.96% (higher).

Inventory/Revenue

31.47 %

YoY

2.96%

Last updated:

Inventory to Revenue Ratio of Acrobiosystems Co is 2025 31.47 % . Inventory to Revenue Ratio of Acrobiosystems Co was 2024 30.56 % . It decreases by 2.96% higher compared to the previous year.

The Acrobiosystems Co Inventory/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory/Revenue
Date
Inventory/Revenue
Jan 1, 2018
24.23 CNY
Jan 1, 2019
20.88 CNY
Jan 1, 2020
13.23 CNY
Jan 1, 2021
16.15 CNY
Jan 1, 2022
19.61 CNY
Jan 1, 2023
25.15 CNY
Jan 1, 2024
30.56 CNY
Jan 1, 2025
31.47 CNY
The Acrobiosystems Co Inventory/Revenue history
YEARInventory/RevenueYoY
31.47 %+2.96%
30.56 %+21.53%
25.15 %+28.22%
19.61 %+21.44%
16.15 %+22.08%
13.23 %-36.65%
20.88 %-13.84%
24.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Inventory to Revenue Ratio of Acrobiosystems Co is 31.47 % in 2025.

Inventory to Revenue Ratio of Acrobiosystems Co changed from 30.56 % to 31.47 %, representing a 2.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory to Revenue Ratio Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The Inventory/Revenue ratio shows what percentage of revenue is held as inventory. Rising ratios may indicate slowing demand or inventory management issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory to Revenue Ratio's Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co